Related Experiment Video
Updated: Jun 10, 2026
12:22
The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
[Molecular targeted therapy for advanced renal cell carcinoma]
1Department of Urology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 22, 2010
Summary
New oral targeted therapies like sorafenib and sunitinib are revolutionizing advanced renal cell carcinoma treatment in Japan. Managing their unique side effects is key to maximizing effectiveness and improving surgical outcomes.
Area of Science:
- Oncology
- Pharmacology
Context:
- Advanced renal cell carcinoma (RCC) treatment landscape in Japan.
- Introduction of oral molecular targeted drugs (sorafenib, sunitinib) in 2008.
- Upcoming approvals of everolimus and other VEGF receptor inhibitors.
Purpose:
- To highlight the shift in advanced RCC treatment strategies.
- To emphasize the importance of managing adverse events associated with targeted therapies.
- To explore the potential of neoadjuvant targeted therapy for surgical management.
Summary:
- Sorafenib and sunitinib offer oral administration for advanced RCC, contrasting with older injectable therapies.
- Effective management of adverse events is crucial for optimizing outcomes with these novel agents.
- Neoadjuvant targeted therapy may enhance surgical options for unresectable or large kidney tumors.
Impact:
- Dramatically changing treatment paradigms for advanced renal cell carcinoma.
- Improving therapeutic options through targeted drug development.
- Potential for improved surgical success rates with neoadjuvant approaches.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...